Yahoo Web Search

Search results

1. • 

     Could This Drug News Lift AbbVie's Stock?

     Motley Fool· 1 year ago

     Consider AbbVie's (NYSE: ABBV) crown jewel drug, Humira, which hauled in $21.2 billion in revenue in 2022. The good news is that AbbVie knew this day...

2. • 

     Why AbbVie Stock Fell Today

     Motley Fool· 7 months ago

     Shares of AbbVie (NYSE: ABBV) were down 5.4% as of 2:00 p.m. ET Friday, even after the pharmaceuticals giant announced slightly better-than-expected...

3. • 

     AbbVie Stock Shows Improved Relative Price Strength

     Investor's Business Daily· 1 year ago

     AbbVie stock had its Relative Strength (RS) Rating upgraded from 69 to 76 Thursday -- a welcome improvement, but still shy of the 80 or higher score you...

4. • 

     AbbVie Insiders Sell US$8.4m Of Stock, Possibly Signalling Caution \

     Simply Wall St. via Yahoo Finance· 11 months ago

     Over the past year, many AbbVie Inc. (NYSE:ABBV) insiders sold a significant stake in the company...

5. • 

     AbbVie Results Fall But The Drop Isn't As Severe As Expected; Shares Climb

     Investor's Business Daily· 10 months ago

     Drug maker AbbVie on Thursday reported second-quarter profit and sales that fell from a year earlier...

6. • 

     AbbVie's Blockbuster Is Falling Fast. Time to Sell?

     Motley Fool· 1 year ago

     Last week wasn't a great one for a lot of pharmaceutical stock investors. Shares of AbbVie (NYSE: ABBV) dropped by about 8% on Thursday, April 27. The...

7. • 

     Better Growth Stock: Vertex Pharmaceuticals vs. AbbVie

     Motley Fool· 1 year ago

     Vertex Pharmaceuticals (NASDAQ: VRTX) and AbbVie (NYSE: ABBV) both beat last year's bear market....

8. • 

     What Could This Drug News Mean for AbbVie?

     Motley Fool· 2 years ago

     In late July, AbbVie (NYSE: ABBV) applied for a new indication with the European Medicines Agency (EMA) for Rinvoq to treat adult patients with...

9. • 

     AbbVie Is Set to Lose on Its Biggest Blockbuster. Here's Why You Shouldn't Worry.

     Motley Fool· 1 year ago

     AbbVie (NYSE: ABBV) boasts a portfolio of drugs across immunology, neuroscience, aesthetics,...

10. • 

      The Zacks Analyst Blog Highlights AbbVie, Salesforce, General Electric, The TJX Companies and UBS...

      Zacks via Yahoo Finance· 1 month ago

      For Immediate Release Chicago, IL – April 10, 2024 – Zacks.com announces the list of stocks featured...